ClinicalTrials.gg
Not yet recruitingNCT06683963Updated Nov 12, 2024

AI-Assisted TelerehabiLitAtion System (ATLAS) for Post-discharge Continuation of Rehabilitative Care

An interventional study of Rebee in Rehabilitation and Deconditioning, sponsored by SingHealth Community Hospitals. Not yet recruiting. Open to participants aged 60 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by SingHealth Community Hospitals · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
60 Years to 99 Years
Sex
All
01

Study summary

The study team proposes ATLAS (AI-Assisted TelerehabiLitAtion System) a two-part solution. The first-Rebee AI-assisted telerehabilitation device-assists in inpatient rehabilitation, and allows patients to continue with their physical rehabilitation when discharged and waiting for Day Rehabilitation Centre (DRC). The second-a structured programme to train and familiarise patients and caregivers to Rebee over patients' Community Hospital (CH) inpatient rehabilitation stay-adopts an evidence-based approach to increase uptake and adherence to Rebee.

02

Conditions studied

  • Rehabilitation
  • Deconditioning
03

In context

Lead sponsor

SingHealth Community Hospitals is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Rehabilitation Diagnostic Group (RDG): Total Knee Replacement / Deconditioning
  2. Age 60 and above
  3. Speak English/Mandarin
  4. Able to follow instructions, no cognitive impairment
  5. No MDRO (MultiDrug Resistant Organism)
  6. Suitable and able to wear motion sensor on upper and lower limbs
  7. Suitable and able to engage in Rebee exercises

Exclusion criteria

Exclusion Criteria:

  1. Not under RDG: Total Knee Replacement / Deconditioning
  2. Below 60 years old
  3. Unable to speak English/Mandarin
  4. Cognitive impaired, unable to follow instructions
  5. Has MDRO
  6. Not suitable to wear motion sensor on upper and lower limbs
  7. Refusal to participate / give
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • No intervention
    Control - usual care

    Business as usual in community hospital, no added device intervention

  • Experimental
    Intervention - Rebee

    Addition of Rebee device during and after community hospital stay

    Device: Rebee

Interventions

  • DeviceRebee

    Tablet device with accompanying sensor device. Tablet device is preloaded with exercises, to be taught to patients during their hospital stay, and to be continued post-discharge

06

What researchers measure

Primary outcomes

  1. Change in Modified Barthel Index scores from baseline to 4, 8, and 12 weeks

    Modified Barthel Index (MBI) measures ability to complete activities of daily living (ADLs). Scores range from 0 to 100. A higher score represents more independence, a lower score indicates more assistance needed (ie less independent). 0-20: Total dependence, 21-60: Severe dependence, 61-90: Moderate dependence, 91-99: Slight dependence, 100: Independence.

    Time frame: from recruitment (week 0) till end of study at 12 weeks

Secondary outcomes

  1. Change in Quality of Life scores from baseline to 4, 8, and 12 weeks

    Quality of Life as measured using EQ-5D-5L. Has two components to this instrument: 1. EQ-5D descriptive system * 1 to 5 for each dimension * A higher score represents "worse health status" (i.e., more severe problems with dimension). 2. EQ visual analogue scale (EQ VAS) * 0 to 100 * A higher score represents "better health status" (i.e., overall current health status).

    Time frame: from recruitment (week 0) till end of study at 12 weeks

  2. Change in Patient Activation Level from baseline to 4, 8, and 12 weeks

    Patient Activation Level measured using PAM-13 Score from 0 to 100 Higher scores indicate greater patient activation

    Time frame: from recruitment (week 0) till end of study at 12 weeks

  3. Readmission rates to hospital within 30 days of discharge

    e.g. 0 means no readmissions back to hospital within 30 days of discharge occured

    Time frame: within 30 days from discharge date

  4. Change in Joint range of motion from baseline to 4, 8, and 12 weeks

    Measured Joint Range of operated knee for patients with total knee replacement (TKR) Joint range will be measured for knee Extension and well as knee Flexion

    Time frame: from recruitment (week 0) till end of study at 12 weeks

  5. Length of Stay in Community Hospital reported in days

    Length of (inpatient) Stay in Community Hospital Reported in days, as measured by Discharge Date minus Admission Date e.g. if Discharge Date is 3/11/2024, and Admission Date is 1/11/2024, patient stayed for 2 days as an inpatient in the community hospital

    Time frame: From recruitment (week 0) till end of study at 12 weeks

  6. Change in STS (sit to stand) score from baseline to 4, 8, and 12 weeks

    Time taken to Sit to Stand 5 times, calculated in seconds A higher score represents taking a longer time to complete 5 times sit to stand.

    Time frame: from recruitment (week 0) till end of study at 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2024; primary completion for Nov 2025, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Nov 12, 2024
StartEst.
Dec 2024
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2025
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06683963
Lead sponsor
SingHealth Community Hospitals
Collaborators
Rebee Health, Jurong Community Hospital
Responsible party
Low Lian Leng (A/Prof, SingHealth Community Hospitals) — Principal investigator
First posted
Nov 12, 2024
Start date
Dec 2024 (estimated)
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Nov 12, 2024

Study contacts

Lian Leng Low
Contact
low.lian.leng@singhealth.com.sg
+6563265872
Charmaine Tan
Contact
charmaine.tan.y.m@singhealth.com.sg
+6569703029

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion